Cyclin dependent kinase inhibitors
The invention relates to cyclin dependent kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer.
1. A method of treating a subject suffering from breast cancer or prostate cancer, the method comprising administering to subject in need thereof a therapeutically effective amount of a compound capable of stabilizing the interaction of a cyclin-dependent kinase and a cdk inhibitor, or a compound capable of stabilizing an inactive conformation of a cyclin-dependent kinase and/or a complex of a cyclin-dependent kinase and a cyclin, such that the subject is treated wherein the compound is selected from the group consisting of 1-(5-methyl-thiophen-2-yl)-3-phenyl-propenone, 4-t-butyl-2-nitro-aniline, 3-amino-1-sulfanylidene-5,6,7,8-tetrahydroisothiochromene-4-carbonitrile, and 4-p-tolylamino-[1,2]naphthoquinone”.
2. The method of claim 1 , wherein the cdk inhibitor is p27.
3. The method of claim 2 , wherein the compound is selected from
4. The method of claim 1 , wherein the cancer is breast cancer and the compound is 1-(5-methyl-thiophen-2-yl)-3-phenyl-propenone.
5. A method for inhibiting breast cancer or prostate cancer cell proliferation, comprising contacting a breast cancer cell or a prostate cancer cell with a compound capable of stabilizing an interaction between a cyclin dependent kinase and p27, such that cancer cell proliferation is inhibited wherein the compound is selected from the group consisting of 1-(5-methyl-thiophen-2-yl)-3-phenyl-propenone, 4-t-butyl-2-nitro-aniline, 3-amino-1-sulfanylidene-5,6,7,8-tetrahydroisothiochromene-4-carbonitrile, and 4-p-tolylamino-[1,2]naphthoquinone”.
6. The method of claim 5 , wherein the cell is a breast cancer cell and the compound is 1-(5-methyl-thiophen-2-yl)-3-phenyl-propenone.
7. A method of treating a subject suffering from breast cancer or prostate cancer, the method comprising administering to subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of 1-(5-methyl-thiophen-2-yl)-3-phenyl-propenone, 4-t-butyl-2-nitro-aniline, 3-amino-1-sulfanylidene-5,6,7,8-tetrahydroisothiochromene-4-carbonitrile, and 4-p-tolylamino-[1,2]naphthoquinone, such that the subject is treated.
8. A method for inhibiting breast cancer or prostate cancer cell proliferation, comprising contacting a breast cancer cell or a prostate cell with a compound selected from the group consisting of 1-(5-methyl-thiophen-2-yl)-3-phenyl-propenone, 4-t-butyl-2-nitro-aniline, 3-amino-1-sulfanylidene-5,6,7,8-tetrahydroisothiochromene-4-carbonitrile, and 4-p-tolylamino-[1,2]naphthoquinone, such that breast cancer or prostate cancer cell proliferation is inhibited.